Full clearance of donor mtDNA was observed after 3 weeks (Figure 1) .
The degree of heteroplasmy we noticed after platelet infusion (30-70%) ( Figure 1 ) was similar to that detected in most patients in the study of Carew et al. 5 Since platelet counts are frequently low in CLL patients repeated platelet transfusions are necessary. The untreated group of patients in the previous study had an average lower disease stage and therefore might not have received platelets within 3 weeks prior to sampling. In contrast, toxicity of chemotherapy leads frequently to thrombocytopenia and subsequent treatment with platelet concentrates.
There is no indication in the previous paper that patients with prior platelet infusions were excluded from the study or if the blood samples were taken at a certain interval after the end of therapy or platelet infusion. However, the very high frequency of high level heteroplasmic mutations in some of the treated patients, as well as the almost identical picture we obtained after sequence analysis of patients following platelet infusion, led us to the conclusion that this is rather caused by donor platelets and unlikely the consequence of chemotherapy.
Determination of mtDNA mutations can only be reliably performed at least 3 weeks after administration of blood products to avoid detection of donor mtDNA. Alternatively, a recently described procedure using special conditions for blood collection to eliminate disturbing platelets could be employed for isolation of PBMC. 6 The high level of heteroplasmy observed by Carew et al. could be explained by selective advantage. However, we would not expect that in one patient, 12 distinct mutations can have a selective advantage leading to similar high levels of heteroplasmy. Especially for synonymous heteroplasmic mutations a selective pressure is most unlikely.
Epidemiological and geographic differences between individuals complicate the statistical interpretation of mtDNA mutations if they are compared to the Cambridge reference sequence. Therefore, analysis of therapy-induced mtDNA mutations should be carried out on matched patients samples. Ideally, buccal swabs, urine sediment or normal leucocytes isolated by FACS sorting before initiation of therapy would be the most appropriate reference material for screening of chemotherapy-induced mtDNA mutations.
In conclusion, analysis of mtDNA mutations in peripheral blood samples from patients with a recent history of donor platelet transfusion should be interpreted consciously.
Clonotypic analysis of acute lymphoblastic leukemia with a double TEL-AML1 fusion at onset and relapse The TEL-AML1 (ETV6-RUNX1) fusion is the most common genetic alteration in childhood acute lymphoblastic leukemia (ALL). 1, 2 Lines of evidence demonstrated the prenatal origins of TEL-AML1 and the requirement of additional complementary genetic events leading to overt leukemia. 3, 4 Ford et al 5 and Konrad et al 6 recently demonstrated that TEL-AML1-positive ALL cells in late relapse were derived from a preleukemic clone not eliminated by initial chemotherapy, suggesting that additional molecular events within the common preleukemic clone give rise to a new leukemia as a conventional relapse. A recent report from Austrian BFM cooperative study group revealed that duplication of TEL-AML1 was observed in approximately 15% of TEL-AML1-positive ALL cases as one of the secondary genetic abnormalities. 7 However, it remains uncertain whether or not duplication of TEL-AML1 is sufficient to generate overt leukemia. To clarify this point, the clonotypic analysis of late relapsed cases with double TEL-AML1 fusion would be informative.
We recently experienced a TEL-AML1-positive ALL patient with a double fusion who relapsed 3 years after cessation of treatment. Cytogenetic studies at onset showed a pseudodiploid karyotype with or without trisomy 21 ( Figure 1a ). In FISH analysis at onset, leukemia cells had two TEL-AML1 fusion signals and were divided into two almost equal populations with (two native AML1 signals) or without (one native AML1 signal) trisomy 21 (Figure 1b and c) . At relapse, all of the leukemia cells had two TEL-AML1 fusion signals lacking trisomy 21 (Figure 1b  and c) . Deletion of the normal TEL allele was not observed both at onset and relapse (Figure 1b and c) . The analysis of clonal rearrangements of Ig and TCR genes are then performed (Figure 1d ). Both diagnostic and relapsed leukemia cells had identical rearrangements of the immunoglobulin (Ig) k gene and DH5-18/JH4 joining of Ig heavy-chain gene, but showed different V H segment. Sequence analysis of the N-region within the V H /D junction revealed no significant homology, indicating that both initial and relapsed clones could independently arise from a common precursor having DH5-18/JH4 rearrangement. In the TCR d gene, a Dd2/Dd3 rearrangement was detected at diagnosis, while neither the Dd2/Dd3 rearrangement nor further rearrangement to D/V or D/V/J was detected at relapse. Germline PCR demonstrated that the TCR d gene at relapse remained germ line. In the TCR g gene, two independent rearrangements were detected at onset, none of which was detected at relapse in semiquantitative PCR using clonespecific primers. Conversely, the third rearrangement, Vg2/Jg2.3, observed at relapse constituted approximately 1 of 10 4 cells at onset.
These results indicated that the relapsed leukemia clone was not directly evolved from the major clone at onset, but instead was from a common preleukemic clone, which existed at onset of the disease as a very minor population. Both initial and relapsed leukemia cells had a double TEL-AML1 fusion, suggesting that duplication of the TEL-AML1 fusion could be present in the common preleukemic clone, but this is insufficient to generate overt leukemia by itself. Since the extra chromosome 21 disappeared at relapse, trisomy 21 is not a critical secondary event, but rather an additional event subsequent to the generation of overt leukemia at least in our case. Accordingly, secondary chomosome abnormalities including duplication of TEL-AML1 and extra chromosome 21 is insufficient for generating overt leukemia at least in the present case.
In some cases of childhood ALL, it has been reported that the FLT3 receptor tyrosine kinase is constitutively activated by internal tandem duplication and small in-frame deletion of the juxtamembrane domain, or by a D835/I836 mutation within the receptor activation loop. 8 Therefore, the FLT3 gene in the patient's leukemia cells was analyzed by PCR. However, leukemia cells at onset and at relapse had no mutations in the juxtamembrane domain or the activation loop (data not shown), indicating that mutation of the FLT3 gene was not implicated as an additional genetic event during leukemogenesis in the present case. The identification of critical genetic mutation 2,3 Direct sequencing of PCR products was performed to determine the clonality. A PCR reaction to detect the germline configuration of the TCR d gene was carried out using the intron sequence between Dd2 and Dd3. Semiquantitative PCR was also performed using clone-specific primers. N-terminal sequence of VH/D junction was 'GGGGGGGGGAGG' at onset and 'AAGATCGACTACG' at relapse. Assumed gene status of leukemia cells (at onset and relapse) and common preleukemic clone is indicated.
Letters to the Editor
Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia Adult patients with advanced hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis because of high rate of relapse. For patients with recurrent disease, salvage chemotherapy or intensive conditioning followed by a second HSCT may be applied; however, aggressive chemotherapy for patients who relapse within 100 days after transplantation is associated with a high mortality and a low rate of complete remission. Even in case of late relapse, long-term survivors are few, although temporary complete remissions (CR) have been restored. Donor lymphocyte infusion (DLI) is regarded as one of the main therapeutic options for relapsed hematological malignancies after allo-HSCT. However, its effect has been confirmed only in early-stage of chronic myelogenous leukemia (CML) in contrast to advanced-stage of CML and other refractory hematological malignancies. Prophylactic DLI exhibited definite effect on the patients with highly aggressive hematological malignancies that had short doubling time. It is also known that DLI could be followed by high rate of severe graft-versus-host disease (GVHD), sometimes, pancytopenia and infection. 1 Many studies have demonstrated that in vivo granulocyte colony stimulating factor (G-CSF) could modify the function of lymphocytes in peripheral blood harvest. 2, 3 Recently, we reported that the infusion of donor G-CSF-mobilized peripheral blood progenitor cells (GPBPC) instead of donor lymphocytes showed a superantileukemic effect and this approach may accompany the decrease of infusion-related GVHD and rarely be complicated with pancytopenia. 4 So, we hypothesize that the prophylactic GPBPC infusion can induce antileukemic effect and lower the incidence of relapse with more safety. Here, we report the preliminary results from trials of allo-HSCT followed by planned prophylactic GPBPC infusion in patients with high-risk hematological malignancies.
From May 2001 to March 2004, 24 patients with hematological malignancies who had a high risk of relapse were allocated on an intend-to-treat basis to allo-HSCT followed by prophylactic GPBPC infusion. All the healthy donors and the recipients signed the consent form for stem cell collection and transplantation and stem cell cryopreservation for later prophylactic GPBPC infusion. Hematological malignancies with high risk of relapse were defined as acute leukemia in the first complete remission (CR1) with unfavorable cytogenetic abnormalities such as positive Ph chromosome, acute leukemia in more than CR1 status or in nonremission state, CML in accelerate phase (AP) and blast crisis (BC), myelodyplastic syndrome-refractory anemia with excess blast (MDS-RAEB) and primary refractory lymphoma. Among the 24 patients, seven were AML in nonremission state, one was in the third CR, five were ALL in nonremission state, three were Ph þ ALL in CR1 after Glivec therapy, six patients were CML in AP and BC, the other two patient were MDS-RAEB. All patients underwent HLA identical-sibling transplantation. The source of stem cells were G-CSF mobilized peripheral blood stem cells (PBSCs) for 13 patients and the mixture of G-CSF-mobilized bone marrow cells and PBSCs for the other 11 patients. The median age of the 24 HSCT recipients was 32 years (range, 12-64 years).
